Glenmark Pharmaceuticals has introduced a drug to treat the coronavirus. The company gave this information in a statement on Saturday. Glenmark said on Saturday that it has launched the antiviral drug Favipiravir under the brand name FabiFlu to treat mild and less symptomatic Coronavirus patients.
The Mumbai-based company said on Friday that it received approval from the Drug Controller General of India (DGCI) to manufacture and market the drug. The company said that FabiFlu is the first food-based favipiravir drug to treat Covid-19, which has been approved.
Glenmark Pharmaceuticals chairman and managing director Gracias Saldanha said, "This approval has come at a time when coronavirus cases in India are increasing more rapidly than before. This has put our healthcare system under great pressure". He hoped that the availability of effective treatment like FabiFlu would help reduce this pressure to a great extent.
Saldanha said that in clinical trials, FabiFlu showed fairly good results on patients suffering from mild infection of the coronavirus. He added that in addition to this it is a food drug which is a convenient treatment option. He said that the company will work closely with the government and the medical community to make this drug easily available to patients across the country. Global trials already show 80-88% efficiency.
This medicine will be available at the price of Rs 103 per tablet on the advice of a doctor. The dosage is 1800mg tablet on day 1 and 800mg for 14 days. Glenmark Pharma said that patients with minor infections who are suffering from diabetes or heart disease can also be given this medicine.
According to the Health Ministry, a record 14,516 cases of coronavirus were reported in the country on Saturday. Now the number of people infected by this epidemic in the country has increased to 3,95,048. This epidemic has killed 12,948 people in the country so far.